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Excluding the 5 patients who died and the 10 who had permanent
postoperative deficits, there remained 79 patients available for follow-up
and at risk of subsequent persistent stroke and death.
This is how, in 1970, Fields and colleagues analysed the data
from the Joint Study of Extracranial Arterial Occlusion, which
had randomly allocated patients with bilateral carotid stenosis
to carotid endarterectomy or medical treatment.1 Among the
patients who had survived surgery and were ‘available for
follow-up’, a 26% reduction in the risk of recurrent transient
ischaemic attacks, stroke, or death was observed, compared
with patients who had received conventional treatment
(P = 0.02). Around the same time Bradford Hill, in the ninth
edition of his Principles of Medical Statistics, pointed out that
excluding patients after ‘admission to the treated or control
group’ may affect the validity of clinical trials and that ‘unless
the losses are very few and therefore unimportant, we may
inevitably have to keep such patients in the comparison and
thus measure the ‘intention to treat’ in a given way, rather than
the actual treatment’.2 Indeed, when several years later Sackett
and Gent3 re-analysed the study according to this intention to
treat principle the results were less convincing: the reduction in
the risk was 17% (P = 0.09) (Figure 1).
In more recent years, the debate has shifted from anecdotal
evidence of bias in single trials to more sophisticated 
‘meta-epidemiological’ research, based on many trials and
meta-analyses.4 Schulz and colleagues5 pioneered this
approach when they assessed the methodological quality of 250
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trials from 33 meta-analyses from the Cochrane Pregnancy and
Childbirth Database and examined the association between
dimensions of trial quality and estimated treatment effects.
Compared with trials in which authors reported adequately
concealed treatment allocation, failure to prevent fore-
knowledge of treatment allocation was associated, on average,
with an exaggeration of treatment effects by 30–40%. Trials that
were not double-blind also yielded larger effects. These bias
effects were subsequently confirmed in several other studies.6
There is thus convincing empirical evidence that trials of lower
methodological quality that are susceptible to selection bias,
performance bias, or detection bias produce, on average, larger
treatment effects than trials of higher quality that avoided or
minimized such biases.
What about attrition bias? So far three studies examined the
influence of this type of bias, which, as the example of the Joint
Study of Extracranial Arterial Occlusion shows can be of great
importance. Schulz et al. compared trials that reported
exclusions with trials that either explicitly reported no
exclusions or gave the impression that no exclusions had taken
place.5 The other two studies assessed the quality of reporting,
rather than methodological quality. Kjaergard et al. compared
trials that reported adequately on attrition (independent of
whether exclusions occurred) to trials with inadequate
reporting.7 Similarly, Balk et al.8 assessed whether dropouts had
been recorded (either explicitly or by reporting the number
enrolled and the number evaluated). Schulz et al. found little
difference in effect estimates whereas the Kjaergard and Balk
studies found trends in opposite directions. The methods used
to assess attrition were unsatisfactory in all cases, because
reports often omit important methodological details.6 In
particular, it is problematic to deduce that a trial was analysed
according to the intention to treat principle if no exclusions are
reported.9 And it is equally problematic to assume that an
analysis described as intent to treat did in fact include all
patients, according to random allocation.10
The elegant study by Tierney and Stewart11 for the first time
directly assesses the impact of attrition bias. Stewart and
colleagues have co-ordinated individual patient data meta-
analyses of clinical trials in oncology for many years and now
present a comparison of the results from their analyses, which
invariably followed the intention to treat principle with those
done by the original investigators, which often excluded some
or many patients. The results confirmed what methodologists
had been suspecting for some time: pooled analyses of trials
with patient exclusions showed more beneficial effects of the
experimental treatment than analyses based on all or most
patients randomized. It therefore seems likely that the earlier
studies5,7,8 either suffered from measurement error due to
incomplete reporting or assessed an inappropriate proxy
measure, reporting quality.12 The effects of attrition bias in
these meta-analyses were modest in most cases, but, as Tierney
and Stewart point out, they may well underestimate the extent
of bias in other situations. Investigators who participate in
collaborative meta-analyses of cancer trials are probably
methodologically more astute and not representative of all
investigators in this field, and certainly not representative of
trialists in general. Of note, although the bias will in general
lead to exaggerated treatment effects, Stewart and Tierney also
show that it can go in either direction, and predicting its effect
in a specific situation will be difficult.
Individual patient data meta-analyses have been described as
the ‘yardstick’ against which other forms of systematic review
and meta-analysis should be measured.13 Tierney and Stewart’s
paper is another example of the power of such analyses, which
in a number of cases have produced definitive answers that
might not have been obtained in any other way.14 Their
approach should be applied more widely to further develop our
understanding of the mechanisms that introduce bias in clinical
trial research.
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